📊 BHC Key Takeaways
Is Bausch Health Companies Inc. (BHC) a Good Investment?
While BHC demonstrates revenue growth of 6.7% YoY and improved net income profitability, the company faces severe structural challenges including negative stockholders' equity of -$554M, dangerously low interest coverage of 1.1x, and a debt burden of $20.8B that consumes nearly the entire asset base. The pharmaceutical sector cyclicality combined with overleveraged capital structure and minimal net margins of 1.5% create significant financial distress risk.
Bausch Health shows improving top-line growth, positive operating income, and solid free cash flow generation, which suggests the core business remains productive. However, the balance sheet is still severely constrained by very high debt, negative equity, and weak interest coverage, leaving little room for operational setbacks. Fundamentals point to a business that is stabilizing, but not yet financially strong enough to offset its leverage risk.
Why Buy Bausch Health Companies Inc. Stock? BHC Key Strengths
- Revenue growth of 6.7% YoY demonstrates market demand and top-line resilience
- Operating margin of 17.7% shows core business operations are fundamentally profitable
- Free cash flow of $1.0B provides some debt servicing capacity despite leverage concerns
- Operating cash flow of $1.4B exceeds capex needs, supporting operational sustainability
- Revenue grew 6.7% year over year, indicating continued business momentum
- Operating income of $1.81B and free cash flow of $1.00B show the company remains cash generative
- Current ratio of 1.47x and quick ratio of 1.08x suggest near-term liquidity is manageable
BHC Stock Risks: Bausch Health Companies Inc. Investment Risks
- Negative stockholders' equity of -$554M indicates balance sheet insolvency and violation of debt covenants risk
- Interest coverage ratio of 1.1x is critically low; minimal earnings cushion for debt service if revenue declines
- Debt-to-assets ratio of 78.8% ($20.8B/$26.4B) shows extreme leverage with limited equity buffer
- Net margin of 1.5% is unsustainably thin; small revenue disruption would eliminate profitability
- Pharmaceutical sector exposure to patent cliffs, regulatory risk, and pricing pressure
- Long-term solvency questionable given negative equity position and refinancing risk
- Long-term debt of $20.82B is extremely high relative to the earnings base
- Negative stockholders equity indicates a highly stressed capital structure
- Interest coverage of 1.1x leaves very limited cushion against refinancing pressure or earnings volatility
Key Metrics to Watch
- Debt reduction trajectory and covenant compliance status
- Interest coverage ratio trend - must improve above 2.5x for financial stability
- Operating margin sustainability and gross margin trends
- Free cash flow adequacy relative to debt service obligations
- Stockholders' equity recovery path to positive territory
- Revenue growth sustainability in competitive pharma environment
- Interest coverage improvement and debt reduction progress
- Free cash flow consistency relative to net income and operating profit
Bausch Health Companies Inc. (BHC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Bausch Health Companies Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BHC Profit Margin, ROE & Profitability Analysis
BHC vs Healthcare Sector: How Bausch Health Companies Inc. Compares
How Bausch Health Companies Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bausch Health Companies Inc. Stock Overvalued? BHC Valuation Analysis 2026
Based on fundamental analysis, Bausch Health Companies Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bausch Health Companies Inc. Balance Sheet: BHC Debt, Cash & Liquidity
BHC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bausch Health Companies Inc.'s revenue has grown significantly by 19% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.62 indicates the company is currently unprofitable.
BHC Revenue Growth, EPS Growth & YoY Performance
BHC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.5B | -$85.0M | $-0.23 |
| Q2 2025 | $2.4B | $10.0M | $0.03 |
| Q1 2025 | $2.2B | -$58.0M | $-0.16 |
| Q3 2024 | $2.2B | -$85.0M | $-0.23 |
| Q2 2024 | $2.2B | $10.0M | $0.03 |
| Q1 2024 | $1.9B | -$64.0M | $-0.17 |
| Q3 2023 | $2.0B | $185.0M | $0.51 |
| Q2 2023 | $2.0B | $26.0M | $0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bausch Health Companies Inc. Dividends, Buybacks & Capital Allocation
BHC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bausch Health Companies Inc. (CIK: 0000885590)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BHC
What is the AI rating for BHC?
Bausch Health Companies Inc. (BHC) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BHC's key strengths?
Claude: Revenue growth of 6.7% YoY demonstrates market demand and top-line resilience. Operating margin of 17.7% shows core business operations are fundamentally profitable. ChatGPT: Revenue grew 6.7% year over year, indicating continued business momentum. Operating income of $1.81B and free cash flow of $1.00B show the company remains cash generative.
What are the risks of investing in BHC?
Claude: Negative stockholders' equity of -$554M indicates balance sheet insolvency and violation of debt covenants risk. Interest coverage ratio of 1.1x is critically low; minimal earnings cushion for debt service if revenue declines. ChatGPT: Long-term debt of $20.82B is extremely high relative to the earnings base. Negative stockholders equity indicates a highly stressed capital structure.
What is BHC's revenue and growth?
Bausch Health Companies Inc. reported revenue of $10.3B.
Does BHC pay dividends?
Bausch Health Companies Inc. does not currently pay dividends.
Where can I find BHC SEC filings?
Official SEC filings for Bausch Health Companies Inc. (CIK: 0000885590) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BHC's EPS?
Bausch Health Companies Inc. has a diluted EPS of $0.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BHC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bausch Health Companies Inc. has a SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BHC stock overvalued or undervalued?
Valuation metrics for BHC: ROE of N/A (sector avg: 15%), net margin of 1.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BHC stock in 2026?
Our dual AI analysis gives Bausch Health Companies Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BHC's free cash flow?
Bausch Health Companies Inc.'s operating cash flow is $1.4B, with capital expenditures of $397.0M. FCF margin is 9.8%.
How does BHC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 1.5% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.47 (avg: 2).